Return to CG131 Overview

Colorectal cancer: diagnosis and management [CG131]

Measuring the use of this guidance

Recommendation: 1.2.5.1

Laparoscopic (including laparoscopically assisted) resection is recommended as an alternative to open resection for individuals with colorectal cancer in whom both laparoscopic and open surgery are considered suitable

What was measured: Proportion of people who had open surgery with no laparoscopic element.
Data collection end: March 2015
39.2%
Number that met the criteria: 7355 / 18773
Area covered: National
Source: National Bowel Cancer Audit. Annual report.

What was measured: Proportion of people who started surgery laparoscopically then converted to open for any reason.
Data collection end: March 2015
8.5%
Number that met the criteria: 1595 / 18773
Area covered: National
Source: National Bowel Cancer Audit. Annual report.

What was measured: Proportion of patients who received laparoscopic surgery.
Data collection end: March 2015
52.3%
Number that met the criteria: 9823 / 18773
Data collection end: March 2016
54%
Data collection end: March 2017
57.8%
Area covered: National
Source: National Bowel Cancer Audit. Annual report.


Recommendation: 1.2.6.2

Consider adjuvant chemotherapy for patients with high‑risk stage II and all stage III rectal cancer to reduce the risk of local and systemic recurrence. [2011]

What was measured: Consider adjuvant chemotherapy for patients with high‑risk stage II and all stage III rectal cancer to reduce the risk of local and systemic recurrence. [2011]
Data collection end: September 2017
60.7%
Number that met the criteria: 7239 / 11932
Area covered: National
Source: National Bowel Cancer Audit. Annual report.


Recommendation: 1.2.8.1

The following are recommended as options for the adjuvant treatment of patients with stage III (Dukes' C) colon cancer following surgery for the condition: capecitabine as monotherapy oxaliplatin in combination with 5‑fluorouracil and folinic acid.

What was measured: Proportion of people undergoing major resection with stage III colonic or rectal cancer (N1 or N2 disease on post-operative staging) who underwent adjuvant treatment with chemotherapy within 3 months of major resection.
Data collection end: March 2016
53%
Number that met the criteria: 1987 / 3765
Data collection end: March 2017
54%
Number that met the criteria: 2263 / 4190
Area covered: National
Source: National Bowel Cancer Audit. Annual report.



 Return to CG131 Overview